Floatz logo

(S)-2-(3-Methyl-1-((3-methyl-1,2,4-oxadiazol-5-yl)methyl)-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)-N-(6-(2-(trifluoromethyl)pyrimidin-5-yl)pyridin-2-yl)propanamide

Osteoarthritis, Knee

Eli Lilly and CompanySmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

30 Active assets in the Osteoarthritis, Knee cohort.

Asset / SponsorPhaseRating
Duloxetine
Orthopaedic Arthroscopy Knee and Shoulder Clinic
Phase 4BBB
Naproxen
Pfizer
Phase 3BB
TRIAMCINOLONE HEXACETONIDE
Kastamonu University
Phase 4BB
DEXAMETHASONE
Poznan University of Medical Sciences
Phase 4BB
Oxycodone
Riku Antero Palanne
Phase 3BB

View all 50 →

Same molecule, other indications

(S)-2-(3-Methyl-1-((3-methyl-1,2,4-oxadiazol-5-yl)methyl)-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)-N-(6-(2-(trifluoromethyl)pyrimidin-5-yl)pyridin-2-yl)propanamide is also rated in:

diabetic neuropathyDormant
B
Indicative ·
57 / 100
View asset →
diabetic neuropathyDormant
B
Indicative ·
57 / 100
View asset →
osteoarthritisDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →